MedTrace Logo

Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia

NCT01153919 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-04-11

No results posted yet for this study

Summary

RATIONALE: Romiplostim may cause the body to make platelets.

PURPOSE: This randomized phase II trial is studying how well romiplostim works in treating hepatitis C-infected patients with thrombocytopenia.

Conditions

Interventions

BIOLOGICAL

romiplostim

Given subcutaneously

DRUG

ribavirin

Given orally

OTHER

placebo

Given subcutaneously

BIOLOGICAL

PEG-interferon alfa-2a

Given subcutaneously

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • University of Southern California

    lead OTHER

Principal Investigators

  • Howard Liebman · University of Southern California

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2014-07-14
Completion
2018-07-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01153919 on ClinicalTrials.gov